La Société progresse vers le dépôt d’une demande de marquage CE en Europe avec 150 patients recrutés ; elle est en bonne voie pour un lancement commercial en 2027 HANGZHOU, Chine, 25 octobre 2025 /PRNewswire/ — Venus Medtech […]
Tag: Venus Medtech (Hangzhou) Inc.
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
Cardiovalve completa la inscripción al estudio TARGET
Cardiovalve completa la inscripción al estudio TARGET para el registro de CE para el reemplazo de la válvula tricúspide La empresa avanza hacia la presentación del marcado CE europeo con 150 pacientes inscritos; en camino […]
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today […]
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed next-generation balloon-expandable dry-tissue transcatheter […]
